Review

cd55 labelled pe monoclonal antibodies (Thermo Fisher)

Thermo Fisher is a verified supplier

Thermo Fisher manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Thermo Fisher cd55 labelled pe monoclonal antibodies

Cd55 Labelled Pe Monoclonal Antibodies, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd55+monoclonal+antibody+pe/bio_rxiv__2024__07__29__601818-69-5-11
Average 90 stars, based on 1 article reviews

cd55 labelled pe monoclonal antibodies - by Bioz Stars, 2026-10

90/100 stars

Images

1) Product Images from "The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)"

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

Journal: bioRxiv

doi: 10.1101/2024.07.29.601818

CD55 shRNA (sc-35012-SH) Plasmid (h) is a pool of 3 different shRNA plasmids

Figure Legend Snippet:

Techniques Used: shRNA, Plasmid Preparation

CD46 and CD55 mRNA expression levels were measured using qRT-PCR in both AML and ALL patients, normalized to the housekeeping gene Beta-actin and results were compared to CD46 and CD55 mRNA expression levels in healthy controls by calculating the RQ value for each one of them. mRNA expression of mCRPs was significantly reduced in AML and ALL patients in comparison with healthy controls. Data are expressed as means ± SD of three independent experiments for each sample done in duplicates and statistical one-way analysis of variance (ANOVA) was used to estimate the significance of difference between the different groups. P<0.001(***).

Figure Legend Snippet: CD46 and CD55 mRNA expression levels were measured using qRT-PCR in both AML and ALL patients, normalized to the housekeeping gene Beta-actin and results were compared to CD46 and CD55 mRNA expression levels in healthy controls by calculating the RQ value for each one of them. mRNA expression of mCRPs was significantly reduced in AML and ALL patients in comparison with healthy controls. Data are expressed as means ± SD of three independent experiments for each sample done in duplicates and statistical one-way analysis of variance (ANOVA) was used to estimate the significance of difference between the different groups. P<0.001(***).

Techniques Used: Expressing, Quantitative RT-PCR, Comparison

The expression level of CD55 in males and females showed a slight reduction in female AML patients compared to males, while the opposite was observed in ALL patients. Data are expressed as means ± SD of three independent experiments for each sample done in duplicates and statistical one-way analysis of variance (ANOVA) was used to estimate the significance of difference between the different groups.

Figure Legend Snippet: The expression level of CD55 in males and females showed a slight reduction in female AML patients compared to males, while the opposite was observed in ALL patients. Data are expressed as means ± SD of three independent experiments for each sample done in duplicates and statistical one-way analysis of variance (ANOVA) was used to estimate the significance of difference between the different groups.

Techniques Used: Expressing

Flow cytometric analysis performed to measure the expression level of CD46 and CD55 in AML and ALL patients showed a significant reduction in CD46 expression in both types of acute leukemia patients. However, for CD55 a significant reduction was observed in AML patients only, while there was no significant difference observed in case of ALL patients. The expression level was calculated with reference to healthy controls. Data are represented as mean values ±SD for each sample done in duplicates, p<0.05 (*).

Figure Legend Snippet: Flow cytometric analysis performed to measure the expression level of CD46 and CD55 in AML and ALL patients showed a significant reduction in CD46 expression in both types of acute leukemia patients. However, for CD55 a significant reduction was observed in AML patients only, while there was no significant difference observed in case of ALL patients. The expression level was calculated with reference to healthy controls. Data are represented as mean values ±SD for each sample done in duplicates, p<0.05 (*).

Techniques Used: Expressing

Flow cytometric analysis of the protein expression level of both CD46 and CD55 in the peripheral blood samples of acute leukemia patients showed a significant reduction in both proteins compared to healthy controls. Results shown are from a representative experiment. (A) CD46 expression in a healthy control. (B) CD46 expression in an AML patient. (C) CD46 expression in an ALL patient. (D) CD55 expression in a healthy control. (E) CD55 expression in an AML patient. (F) CD55 expression in an ALL patient.

Figure Legend Snippet: Flow cytometric analysis of the protein expression level of both CD46 and CD55 in the peripheral blood samples of acute leukemia patients showed a significant reduction in both proteins compared to healthy controls. Results shown are from a representative experiment. (A) CD46 expression in a healthy control. (B) CD46 expression in an AML patient. (C) CD46 expression in an ALL patient. (D) CD55 expression in a healthy control. (E) CD55 expression in an AML patient. (F) CD55 expression in an ALL patient.

Techniques Used: Expressing, Control

Knockdown of CD46 and CD55 protein expression in transfected cells was performed using shRNA silencing plasmids, each consisting of a pool of three different shRNA plasmids and PEI was used as the transfection reagent. Silencing of CD46 and CD55 proteins was done separately in addition to co-silencing of both proteins. Flow cytometric analysis was performed to measure the expression level of both proteins post transfection. Results showed a highly significant reduction in the expression level of both proteins. The percentage of inhibition was calculated relative to nonsilencing shRNA controls (=100%) p<0.001(***). (A) CD46 and CD55 proteins expression level post transfection compared to expression in mock transfected cells. (B) Flow cytometric analysis chart of a representative experiment showing protein expression of CD46 in HSB-2 transfected cells. (C) Flow cytometric analysis chart of a representative experiment showing protein expression of CD55 in HSB-2 transfected cells. (D) Flow cytometric analysis chart of a representative experiment showing protein expression of CD46 and CD55 in mock transfected cells.

Figure Legend Snippet: Knockdown of CD46 and CD55 protein expression in transfected cells was performed using shRNA silencing plasmids, each consisting of a pool of three different shRNA plasmids and PEI was used as the transfection reagent. Silencing of CD46 and CD55 proteins was done separately in addition to co-silencing of both proteins. Flow cytometric analysis was performed to measure the expression level of both proteins post transfection. Results showed a highly significant reduction in the expression level of both proteins. The percentage of inhibition was calculated relative to nonsilencing shRNA controls (=100%) p<0.001(***). (A) CD46 and CD55 proteins expression level post transfection compared to expression in mock transfected cells. (B) Flow cytometric analysis chart of a representative experiment showing protein expression of CD46 in HSB-2 transfected cells. (C) Flow cytometric analysis chart of a representative experiment showing protein expression of CD55 in HSB-2 transfected cells. (D) Flow cytometric analysis chart of a representative experiment showing protein expression of CD46 and CD55 in mock transfected cells.

Techniques Used: Knockdown, Expressing, Transfection, shRNA, Inhibition

Co-silencing of CD46 and CD55 expression in transfected cells led to a highly significant reduction in the expression of both proteins(p<0.001). A significant difference was observed between CD46 and CD55 knockdown(p<0.05).The percentage of inhibition was calculated relative to nonsilencing shRNA controls (=100%). p<0.001(***), p<0.05(*). (B) Flow cytometry analysis chart for CD46 and CD55 expression on HSB-2 cells transfected with combined CD46 and CD55 shRNA silencing plasmids. Dots in the third quadrant show the double negative expression for both CD46 and CD55 after knockdown of both CD46 and CD55 genes using combined CD46 and CD55 silencing shRNA plasmids.

Figure Legend Snippet: Co-silencing of CD46 and CD55 expression in transfected cells led to a highly significant reduction in the expression of both proteins(p<0.001). A significant difference was observed between CD46 and CD55 knockdown(p<0.05).The percentage of inhibition was calculated relative to nonsilencing shRNA controls (=100%). p<0.001(***), p<0.05(*). (B) Flow cytometry analysis chart for CD46 and CD55 expression on HSB-2 cells transfected with combined CD46 and CD55 shRNA silencing plasmids. Dots in the third quadrant show the double negative expression for both CD46 and CD55 after knockdown of both CD46 and CD55 genes using combined CD46 and CD55 silencing shRNA plasmids.

Techniques Used: Expressing, Transfection, Knockdown, Inhibition, shRNA, Flow Cytometry

Viability of HSB-2 cells was analyzed after silencing of CD46 and CD55 protein expression separately as well as combined silencing of both proteins using shRNA plasmids. Cell viability was assessed using MTT reagent in the presence of NHS as a source of complement. Cells had a reduced viability in the absence of CD46 (p<0.001) and CD55 (p<0.01) as well as in CD46 and CD55 co-silenced cells (p<0.01). P<0.01 (**), p<0.001 (***).

Figure Legend Snippet: Viability of HSB-2 cells was analyzed after silencing of CD46 and CD55 protein expression separately as well as combined silencing of both proteins using shRNA plasmids. Cell viability was assessed using MTT reagent in the presence of NHS as a source of complement. Cells had a reduced viability in the absence of CD46 (p<0.001) and CD55 (p<0.01) as well as in CD46 and CD55 co-silenced cells (p<0.01). P<0.01 (**), p<0.001 (***).

Techniques Used: Expressing, shRNA

other:

Article Title: The decay-accelerating factor (CD55) in acute leukemia patients and its query implication in cancer pathogenesis.
Article Snippet: CD55 monoclonal antibody (PE, Thermo Fisher Scientific, MHCD5504) and CD46 monoclonal antibody (FITC, Thermo Fisher Scientific, MA5-49,013) were used to measure the level of both proteins.

Image Search Results

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet:

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: shRNA, Plasmid Preparation

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet: CD46 and CD55 mRNA expression levels were measured using qRT-PCR in both AML and ALL patients, normalized to the housekeeping gene Beta-actin and results were compared to CD46 and CD55 mRNA expression levels in healthy controls by calculating the RQ value for each one of them. mRNA expression of mCRPs was significantly reduced in AML and ALL patients in comparison with healthy controls. Data are expressed as means ± SD of three independent experiments for each sample done in duplicates and statistical one-way analysis of variance (ANOVA) was used to estimate the significance of difference between the different groups. P<0.001(***).

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: Expressing, Quantitative RT-PCR, Comparison

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet: The expression level of CD55 in males and females showed a slight reduction in female AML patients compared to males, while the opposite was observed in ALL patients. Data are expressed as means ± SD of three independent experiments for each sample done in duplicates and statistical one-way analysis of variance (ANOVA) was used to estimate the significance of difference between the different groups.

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: Expressing

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet: Flow cytometric analysis performed to measure the expression level of CD46 and CD55 in AML and ALL patients showed a significant reduction in CD46 expression in both types of acute leukemia patients. However, for CD55 a significant reduction was observed in AML patients only, while there was no significant difference observed in case of ALL patients. The expression level was calculated with reference to healthy controls. Data are represented as mean values ±SD for each sample done in duplicates, p<0.05 (*).

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: Expressing

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet: Flow cytometric analysis of the protein expression level of both CD46 and CD55 in the peripheral blood samples of acute leukemia patients showed a significant reduction in both proteins compared to healthy controls. Results shown are from a representative experiment. (A) CD46 expression in a healthy control. (B) CD46 expression in an AML patient. (C) CD46 expression in an ALL patient. (D) CD55 expression in a healthy control. (E) CD55 expression in an AML patient. (F) CD55 expression in an ALL patient.

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: Expressing, Control

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet: Knockdown of CD46 and CD55 protein expression in transfected cells was performed using shRNA silencing plasmids, each consisting of a pool of three different shRNA plasmids and PEI was used as the transfection reagent. Silencing of CD46 and CD55 proteins was done separately in addition to co-silencing of both proteins. Flow cytometric analysis was performed to measure the expression level of both proteins post transfection. Results showed a highly significant reduction in the expression level of both proteins. The percentage of inhibition was calculated relative to nonsilencing shRNA controls (=100%) p<0.001(***). (A) CD46 and CD55 proteins expression level post transfection compared to expression in mock transfected cells. (B) Flow cytometric analysis chart of a representative experiment showing protein expression of CD46 in HSB-2 transfected cells. (C) Flow cytometric analysis chart of a representative experiment showing protein expression of CD55 in HSB-2 transfected cells. (D) Flow cytometric analysis chart of a representative experiment showing protein expression of CD46 and CD55 in mock transfected cells.

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: Knockdown, Expressing, Transfection, shRNA, Inhibition

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet: Co-silencing of CD46 and CD55 expression in transfected cells led to a highly significant reduction in the expression of both proteins(p<0.001). A significant difference was observed between CD46 and CD55 knockdown(p<0.05).The percentage of inhibition was calculated relative to nonsilencing shRNA controls (=100%). p<0.001(***), p<0.05(*). (B) Flow cytometry analysis chart for CD46 and CD55 expression on HSB-2 cells transfected with combined CD46 and CD55 shRNA silencing plasmids. Dots in the third quadrant show the double negative expression for both CD46 and CD55 after knockdown of both CD46 and CD55 genes using combined CD46 and CD55 silencing shRNA plasmids.

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: Expressing, Transfection, Knockdown, Inhibition, shRNA, Flow Cytometry

Journal: bioRxiv

Article Title: The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)

doi: 10.1101/2024.07.29.601818

Figure Lengend Snippet: Viability of HSB-2 cells was analyzed after silencing of CD46 and CD55 protein expression separately as well as combined silencing of both proteins using shRNA plasmids. Cell viability was assessed using MTT reagent in the presence of NHS as a source of complement. Cells had a reduced viability in the absence of CD46 (p<0.001) and CD55 (p<0.01) as well as in CD46 and CD55 co-silenced cells (p<0.01). P<0.01 (**), p<0.001 (***).

Article Snippet: CD46 labelled with FITC and CD55 labelled with PE monoclonal antibodies (ThermoFisher scientific, USA) were used.

Techniques: Expressing, shRNA

Review

cd55 labelled pe monoclonal antibodies (Thermo Fisher)

Structured Review

Images

1) Product Images from "The Contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML)"

Related Articles

other:

Similar Products

Image Search Results